View Older Stories View More Recent Stories
-
Roth Capital Downgrades Alexza Pharma (ALXA) to Neutral
-
Roth Maintains Keryx (KERX) at 'Buy' Following Q2 Results; Long-Term Study Data Still Looks Good
-
Roth Capital Upgrades PowerSecure (POWR) to Buy
-
New CEO Whitaker is Positive for Synta Pharma (SNTA); Roth Affirms at 'Buy' Following Q2 Results
-
Roth Raises Target on Enphase (ENPH) 50% Following Q2 Results and Outlook
-
Energy Focus Announces Pricing of Public Offering of Common Stock
-
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
-
Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
-
Key Takeaways from Hydrogenics' (HYGS) Q2 Report
-
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Capital Starts Sucampo Pharmaceuticals (SCMP) at Buy
-
Roth Capital Starts Alcobra Ltd. (ADHD) at Buy
-
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
-
Streetinsider.com's Hot Lunchtime Reads 07/31:(NQ) (TMUS) (TSLA) (AMCX) (MCUR)
-
New CEO Encouraging, but Plenty of Problems Persist at Dendreon (DNDN) - Roth Capital
-
Bio Blast Pharma (ORPN) IPO Opens, Trades Lower
-
Maxwell (MXWL) Risk-Reward Favorable into Q2 Report on Recent Pullback, FY15 Bus Read Through
-
Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
-
Roth Capital Comments on Pharmacyclics (PCYC) Following Expanded IMBRUVICA Coverage; Affirms 'Buy' Rating
-
Roth Affirms 'Buy' Rating on Stemline (STML); Comments on SL-401 News
-
Pre-Open Stock Movers 7/28: (FDO) (XGTI) (TRLA) Higher; (ACRX) (HZNP) (Z) Lower (more...)
-
Roth Capital Upgrades Prosensa (RNA) to Buy
-
Roth Highlights Two Takeaways from SolarCity's (SCTY) ABS Offering; Maintains 'Buy' Rating
-
Mines Management (MGN) Plans 4,000 Units Offering
-
Roth Positive on Pharmacyclics (PCYC) Following CHMP Recommendation of Imbruvica
-
Applied Genetic Technologies (AGTC) Prices 2M Common Offering at $15/Share
-
AGTC Announces Pricing of Public Offering
-
Notable Analyst Rating Changes 07/24: (RKUS) (UIS) (SEIC) Upgraded; (ANGI) (QCOM) (BA) Downgraded
-
Roth Capital Starts CorMedix (CRMD) at Buy
-
Roth Sees Significant Advantages to TG Therapeutics' (TGTX) TGR-1202 vs. Gilead's (GILD) Zydelig; Reiterates 'Focus Pick' Rating
-
Ligand (LGND) Pressure on GSK's Promacta Data is Overreaction - Roth Capital
-
NHLBI Trial Choice Validates Cytori (CYTX) as Top Stem Cell Player - Roth Capital
-
Notable Analyst Rating Changes 07/22: (AGN) (RLGY) (FANG) Upgraded; (AMZN) (STI) (MTDR) Downgraded
-
Roth Capital Comments on Ligand (LGND) Following SAGE-547 Update
-
Roth Capital Raises PT on Galena (GALE) to $8 Following Zuplenz Licensing News
-
Roth Capital Upgrades Ultra Clean (UCTT) to Buy
-
CymaBay Therapeutics (CBAY) Prices 4M Follow-On at $5.50/Share
-
Roth Capital Upgrades Diamondback Energy (FANG) to Buy
-
Roth Capital Boosts Price Target on TG Therapeutics (TGTX) to $25 on Prelim. TG-1101 Phase 1 Data
-
Roth Encouraged by Progress with Supinoxin; Maintains 'Buy Rating on Rexahn Pharma (RNN)
-
Notable Analyst Rating Changes 07/18: (BC) (AMH) (PLXS) Upgraded; (RP) (AMD) (NUS) Downgraded
-
Roth Capital Affirms Regeneron (REGN) at 'Buy'; Comments on Eylea Phase III VIVID-DME Two-Year Data
-
Pre-Open Stock Movers 7/18: (ICLD) (GTIV) (SWKS) (GOOG) Higher; (RP) (NQ) (AMD) Lower (more...)
-
Roth Capital Sees Prelim. Q2 Revenue Numbers from Ligand (LGND) as Just the Beginning of More Success to Come
-
Roth Capital Starts PEDEVCO Corp (PED) at Buy
-
Roth Capital Starts Nimble Storage (NMBL) at Buy
-
Plug Power Shipments/Bookings Going as Expected; Roth Issues Commentary Following Analyst Meetings
-
Streetinsider.com's Hot Lunchtime Reads 07/16: (AAPL) (MCP) (MNGA) (YHOO)
-
Roth Capital Encouraged by Removal of CTP-354 Clinical Hold; Has Concert Pharma (CNCE) at 'Buy'
-
Roth Capital Affirms Peregrine Pharma (PPHM) at 'Buy'; Remains Encouraged by Progress in FY14

